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EVALUATING THE UTILITY OF SPECT/CT IMAGING OF ANGIOSOME
PERFUSION IN DIABETIC PATIENTS WITH CRITICAL LIMB ISCHEMIA.
Jessica L. Buckley, Albert J. Sinusas, Mitchel R. Stacy. Section of Cardiovascular
Medicine, Department of Internal Medicine, Yale University School of Medicine, New
Haven, CT.
Impaired lower extremity perfusion is a hallmark of peripheral arterial disease
(PAD) and is particularly problematic in diabetic patients, who suffer from high rates of
PAD, ulceration, and lower extremity amputation. The ability to non-invasively detect
deficits in microvascular perfusion within vascular territories, or angiosomes, of the feet
may provide information related to tissue viability and guide therapeutic interventions. In
this study, we sought to apply single photon emission computed tomography
(SPECT)/CT imaging to quantify volumetric microvascular perfusion within specific
angiosomes containing non-healing foot ulcers in diabetic patients with critical limb
ischemia (CLI). Additionally, we sought to assess the value of SPECT/CT perfusion
imaging for predicting limb salvage in CLI patients undergoing lower extremity
endovascular revascularization.
Forty-one diabetic patients (mean age, 66±12 yrs) with non-healing ulcers and
nine healthy control subjects (mean age, 50±10 yrs) underwent SPECT/CT imaging of
the feet following a resting injection of technetium-99m (99mTc)-tetrofosmin (dose, 550.6
± 37 Mbq). CT images of diabetic feet were segmented into five angiosomes and used for
quantifying relative radiotracer uptake, expressed as standardized uptake values (SUVs).
SUVs were assessed for each CLI patient in the angiosome containing the non-healing
ulcers, while average whole foot perfusion was assessed for healthy control subjects.
Percent change in SPECT SUVs of ulcerated angiosomes was quantified following

endovascular revascularization in patients, and 3-, 6-, and 12-month limb salvage
outcomes were assessed.
SPECT/CT imaging allowed for visualization of perfusion deficits under resting
conditions. 99mTc-tetrofosmin SPECT/CT imaging of angiosome foot perfusion
demonstrated a significant difference in baseline perfusion values (SUVs) between
diabetic patients with CLI and healthy control subjects (p = 0.02). Analysis of baseline
SPECT/CT imaging and ankle-brachial index (ABI) measurements in CLI patients and
healthy control subjects demonstrated a significant and positive relationship between
SPECT/CT angiosome perfusion and ABI (p = 0.01; r = 0.41). Serial evaluation of
relative changes in SPECT angiosome foot perfusion following revascularization
revealed significant quantitative changes in perfusion after treatment, whereas ABI
measurements did not demonstrate significant changes after revascularization. Changes in
SPECT/CT-derived angiosome perfusion significantly differed between patients with and
patients without amputation in the 3 (p = 0.01), 6 (p = 0.03), and 12 (p = 0.03) months
following revascularization.
SPECT/CT imaging provides a useful non-invasive tool for evaluating
microvascular perfusion within specific angiosomes of the foot under resting conditions.
SPECT/CT imaging also allows for serial assessment of sensitive changes in angiosome
microvascular perfusion following revascularization that are undetected by ABI.
Perfusion imaging with SPECT/CT offers a novel quantitative imaging approach for
assessing the efficacy of revascularization strategies targeted at restoring perfusion to
non-healing wounds of the foot and may assist with predicting limb salvage outcomes in
CLI patients undergoing revascularization. Future application of SPECT/CT perfusion

imaging may provide additional value for detection and targeting of ischemic tissue for
therapeutic interventions in the PAD patient population.
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INTRODUCTION
Peripheral Arterial Disease
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis and is
commonly defined as a partial or complete obstruction of at least one noncoronary blood
vessel (3, 4). PAD affects approximately 8 million Americans (5) and it is estimated that
the worldwide prevalence of PAD is 10 percent (6). It is estimated that PAD affects
greater than 200 million people worldwide (3); however, it is likely that many more may
have PAD given that individuals may be asymptomatic. PAD has an increased prevalence
among males and the elderly. Furthermore, the prevalence of PAD increases above 10
percent in individuals over the age of 60 (3). A study approximated the annual cost of
PAD related treatment at 4.37 billion dollars (7). PAD patients are at a high risk for
having a cardiovascular event and the majority die of cardiac or cerebrovascular-related
events (8).
PAD manifests in a wide spectrum of symptoms. Individuals with PAD can be
asymptomatic or have clinical manifestations ranging from intermittent claudication to
limb-threatening ischemia, rest pain, non-healing ulcers, and gangrene. The most
common presentation of PAD is a patient suffering from intermittent pain or cramping in
the legs and/or feet during exercise or exertion that is relieved with rest, which is referred
to as intermittent claudication. The more severe end of the PAD spectrum, rest pain and
non-healing ulcers, and/or gangrene is called critical limb ischemia (CLI). Outcomes for
patients with CLI are alarming, at 1 year, 10 percent will experience a fatal
cardiovascular event and 25 percent will have had an amputation (9). Aggressive
treatment is needed for these patients since progression to amputation is common. CLI

-2results in a mortality rate of 46 percent at 5 years and amputations occur in 27 percent of
patients within the first year (10).
Asymptomatic patients are typically identified after a suspicious physical exam
that identifies weak or absent pedal pulses. Suspected PAD can be confirmed with a
commonly used clinical tool called an Ankle-Brachial Index (ABI). The resting ABI is
obtained by measuring systolic blood pressures at the arms (brachial arteries) and ankles
(dorsalis pedis and posterior tibial arteries) in the supine position by using a Doppler
device. The ABI of each leg is calculated by dividing the higher of the dorsalis pedis or
posterior tibial pressure by the higher of the right or left arm blood pressure. The normal
range for an ABI is 0.9-1.3. Patients with lower extremity claudication will commonly
score below 0.9, however, patients with calcified vessels, especially diabetic patients will
often have falsely elevated ABIs because of the inability to properly compress their
vessels during this exam.
Apart from physical
exam there are several scoring
systems that exist to classify
PAD patients according to their
symptoms, with the most
commonly used system in the
United States being the

Figure 1. Classification systems for PAD patients (1).

Rutherford system, outlined in Figure 1 (1).
Risk factors for PAD echo those of coronary artery disease, namely, family
history, diabetes mellitus (DM), smoking, hypertension, hyperlipidemia (9). However,
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other risk factors. DM, in particular, is associated with more clinical complications, such
as lower extremity amputations and higher mortality (8).
Role of Diabetes Mellitus in PAD
In 2010, there were 25.8 million people in the United States with DM (11). In
2011, it was estimated that 350 million people worldwide were affected by DM (12). The
prevalence of DM in the United States has increased by an alarming 382 percent from
1988 to 2014 (13) and is strongly related with the rise in obesity, where 85.2 percent of
individuals with type 2 DM are overweight or obese (14). Diabetic foot complications are
the leading cause of hospitalization and major or minor amputation, and these
complications represents up to 40 percent of health expenditures in DM patients (12).
DM is a risk factor for PAD, with PAD prevalence rates of 10-40 percent in the DM
patient population (15). DM doubles the chance of developing PAD and it has been
shown that a 1 percent increase in glycated hemoglobin A1c (HA1c), an indicator of
long-term glycemic exposure, is associated with a 26 percent increase in developing PAD
(6, 16). In comparison with patients without DM, PAD is more likely to progress in
patients with DM.
In addition to an increased prevalence of PAD in the setting of DM, DM patients
also have a 12-15 percent risk of developing foot lesions, making DM an important risk
factor for limb amputation (17). Alarmingly, patients with concomitant PAD and DM are
5 to 10 times more likely to have disease progression requiring an amputation (6). DM
foot lesions may start as an uncomplicated area, but risk for amputation increases with
the development of infection in soft tissue (cellulitis) and bones (osteomyelitis). Eight
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severe infection and gangrene, ultimately resulting in 5-8 percent of patients with DM
foot complications undergoing major amputation within 1 year of presentation (12).
Additionally, patients with concurrent PAD and DM foot ulcers experience high
mortality rates, where 50 percent of patients will be dead within 5 years of clinical
presentation (15).
In several large observational studies, PAD was present in up to 50 percent of the
patients with diabetic foot ulcers and was an independent risk factor for amputation (15).
The poor outcomes of ischemic foot ulcers in those with DM is thought to be due to a
combination of factors including, but not limited to, the anatomic distribution of vascular
lesions rendering them more difficult to treat, the association with other abnormalities
such as infection, neuropathy, renal failure, and abnormalities in other vascular territories
such as coronary and cerebral arteries (15). Wound healing is further disturbed by the
complex interaction of several factors, such as poor glycemic control, microvascular
dysfunction, impaired collateral vessel formation, abnormal mechanical loading of the
ulcer, and co-morbidities (15). It is estimated that early detection and appropriate
treatments may prevent up to 85 percent of these amputations (11). A non-invasive
imaging approach able to assess microvascular function in PAD patients is needed but
more so in those with concomitant diabetes for whom the combination of pathology
results in severe and harsh outcomes in a short period of time.
Overview of Diagnostic Tools
Several non-invasive tools have been used to detect and evaluate PAD, including
the ankle-brachial index (ABI), toe-brachial index (TBI), Transcutaneous oxygen

-5pressure (TcPO2), duplex ultrasound, magnetic resonance (MR) imaging, computed
tomography (CT) angiography, single-photon emission computed tomography (SPECT),
and positron emission tomography (PET).

Currently, the ABI is the most recognized

and most widely applied functional measurement used for diagnosis and therapy
monitoring (18). In patients with a history or physical examination suggestive of PAD,
the ABI has good validity as a first-line test in the diagnosis of PAD, as shown by
vascular imaging, with sensitivities ranging from 68 to 84 percent and specificities from
84 to 99 percent (18). However, ABI measurements have disadvantages. Specifically,
ABI is only truly effective at evaluating large vessel obstructions and therefore has
decreased sensitivity in the setting of microvascular disease, can be falsely elevated in
patients with calcified arteries, and has poor reproducibility due to inter-user variability
(7, 19). Of note, approximately 30 percent of CLI patients have normal or near-normal
ABI measurements (19). Additionally, the accuracy of using the ABI for predicting
healed foot ulcers has been shown to be low, with a sensitivity of 0.48 (95% CI, 0.360.61) and specificity of 0.52 (95% CI, 0.42-0.63) (11).
Where ABI fails to obtain an accurate measurement in patients with calcified
arteries, toe-brachial index (TBI) may prove to be a better choice. TBI is obtained in a
similar manner to ABI but uses great toe systolic pressures in the place of ankle and foot
pressures. TBI is useful when ABI measure are thought to be inaccurate or cannot be
obtained because digital arteries are not compressible (19). However, similarly to ABI,
TBI do not localize disease and is not a viable tool in many patients with progressed
disease who have already had their great toes amputated.
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TcPO2 uses a non-invasive diagnostic tool applied to the epidermal surface of the skin to
determine the pO2 level in tissues (20). However, TcPO2 has limited accuracy in the
setting of edema, thick skin, infection, and is time consuming (19). The greatest
weakness of TcPO2 as an assessment tool is its ability to only measure superficial tissue
viability (7). For ulcer healing, the combined sensitivity and specificity of TcPO2 have
been shown to be 0.72 (95% CI, 0.61-0.81) and 0.86 (95% CI, 0.68-0.95), respectively
(11).
For lower extremity anatomical assessment, duplex ultrasound, CT angiography
and MR angiography are routinely used in clinical practice to detect PAD and identify the
location and extent of arterial obstruction. Due to the non-invasive nature, lower risks,
and lower costs, duplex ultrasound is frequently the primary imaging modality used in
patients with PAD; however, ultrasound is not without limitations. Specifically,
ultrasound only permits evaluation of blood flow in major vessels and is not useful for
the assessment of collateral vessel flow (7). Additionally, ultrasound is particularly
challenging in the obese patient with arterial calcifications due to image shadowing (19).
Clinical studies have shown that the quality of ultrasound depends on the user’s level of
experience and that some arterial segments are more easily visible than others. (21). For
example, in some cases (i.e. obesity, gas interpositions), the iliac arteries are more
difficult to visualize and alternative methods, such as CT angiography, MR angiography,
and digital subtraction angiography should be considered (22). CT and MR angiography
can both offer valuable anatomical information. The great advantage of CT angiography
remains the visualization of calcifications, clips, stents, and bypasses (22). CT
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is reduced when it comes to calcified vessels, particularly in the smaller vessels of the
calf and foot (19). In comparison to CT angiography, MR angiography does not require
radiation or iodinated contrast (19). However, MR angiography does use gadolinium
contrast agents, which cannot be used in cases of severe renal insufficiency (GFR, 30
mL/min per 1.73 m2) (22), and MR is hindered in the presence of non-compatible
pacemakers or metal implants (including stents).
Digital subtraction angiography (DSA) remains the gold standard for imaging
tools in assessing PAD since it allows for high spatial resolution imaging of vascular
occlusions (6). DSA is an invasive procedure and carries the risk of complications,
including hematoma, pseudoaneurysm, dissection and arteriovenous fistula (6).
Additionally, DSA requires intra-arterial delivery of iodinated contrast, and is limited in
its inability to characterize vessel walls and thrombus (6). Replacing DSA with a noninvasive alternative may reduce contrast-induced nephrotoxicity, patient discomfort, and
reduce patient costs. Considered as the gold standard for decades, DSA is now reserved
for patients undergoing peripheral interventions, especially concomitant to endovascular
procedures (22). CT and MR angiography are now replacing DSA as routine secondary
imaging methods since they permit a non-invasive assessment of the localization and
extension of vascular lesions and facilitate accurate planning of endovascular and/or
surgical treatment (10).
Assessment of Lower Extremity Perfusion
Since impaired lower extremity perfusion is the main pathophysiological
mechanism of PAD, imaging tools capable of non-invasively evaluating tissue perfusion
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The ability to detect microvascular foot abnormalities may be particularly valuable in the
setting of diabetes, where patients commonly present with concomitant macro- and
microvascular disease. Although studies have attempted to assess perfusion, imaging
modalities such as ultrasound and TcPO2 only look at 2D slices, superficial perfusion, or
have not been readily adopted owing to lengthy acquisition times and reproducibility
concerns (20, 23). Additionally, these tools do not permit quantitative volumetric
assessment of tissue oxygenation or perfusion within different vascular territories of the
foot. Therefore, a clinical need exists for a non-invasive imaging tool capable of
assessing global changes in foot tissue perfusion.
SPECT/CT perfusion imaging of the lower extremities can be performed under
resting conditions and provides quantitative assessment of microvascular perfusion
within three-dimensional (3D) vascular territories, or angiosomes, of the foot. The ability
to identify volumetric abnormalities in microvascular perfusion under resting conditions
can be of significant value in the CLI patient population since many of these patients are
incapable of ambulating for exercise stress testing. SPECT/CT perfusion imaging can be
performed without the need of an intravenous contrast agent, thus offering a useful noninvasive approach for evaluating perfusion in diabetic patients who also commonly
present with impaired renal function.
Nuclear imaging modalities provide high sensitivity and offer potentially novel
methods for the investigation of PAD. SPECT and PET are the primary nuclear imaging
modalities. SPECT imaging also allows for the simultaneous evaluation of multiple
radiotracers targeted at various physiological processes. PET imaging provides increased
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SPECT is more established, less expensive, and more widely available (5). Both SPECT
and PET not only allow for the physiologic assessment of PAD but may also permit
evaluation of molecular events associated with disease progression or treatment response.
Although SPECT and PET provide higher sensitivity, they both also have lower spatial
resolution when compared with CT and MR (submillimeter to ~1 mm resolution) (5).
However, the recent emergence of hybrid SPECT/CT and PET/CT systems has allowed
for the combination of high sensitivity physiologic SPECT and PET imaging with high
resolution anatomic imaging of CT to optimally localize and quantify radiotracer uptake.
Additionally, these hybrid imaging systems now permit correction of attenuation and
partial-volume effects, allowing for more precise radiotracer quantification within
anatomically defined regions of interest (24).
The first nuclear medicine studies examining lower extremity skeletal muscle
blood flow in PAD patients evaluated the clearance rates of 24Na-Chloride, 133Xe, and
99m

Tc-pertechnetate after an intramuscular injection of these radiotracers (25-27). The

development of nuclear medicine later led to two-dimensional imaging of microspheres
and albumin that were radiolabeled with 99mTc, 131I-sodium, and 111In to measure lower
extremity perfusion (28-30). These techniques were not ideal as they required intraarterial injections in order to evaluate blood flow during first pass circulation. The need
for techniques that did not require intra-arterial injections eventually led to the use of
thallium-201 (201Tl) as a perfusion agent for SPECT imaging. 201Tl is a diffusible tracer
with properties similar to potassium, thereby allowing for transport into viable cells via
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both myocardial and skeletal muscle perfusion (32-36). 201Tl perfusion imaging can
provide an estimate of flow over a wide physiologic range since it can be performed after
an intravenous injection at rest or during exercise and has a high first-pass extraction
(~85%) (33). Whole-body 201Tl scintigraphy has been shown to be useful for evaluating
perfusion abnormalities in the lower extremities of PAD patients at rest and during
exercise, and for the detection of perfusion abnormalities in asymptomatic patients
presenting with normal ankle brachial indices (35-37). PAD severity has traditionally
been assessed by determining ratios of activity between non-stenotic and stenotic legs or
by normalizing activity in lower extremity regions of interest to whole-body activity in
the presence of bilateral disease (32, 37, 38). With the emergence of 3D SPECT imaging
systems, it was possible to more accurately detect and localize regions of lower extremity
ischemia under both rest and stress conditions with 201Tl (34). One of the first lowerextremity imaging studies to use 201Tl SPECT for the investigation of PAD evaluated
stress profile curves from multiple transverse images in the leg during reactive hyperemia
with normalization of regional activity to whole-body activity (34). Although 201Tl was
shown to be effective in many studies, its long half-life and imaging characteristics were
less favorable when compared with technetium-99m (99mTc)-labeled radiotracers (5).
This has resulted in the implementation of newer 99mTc-labeled perfusion tracers that
reduce radiation exposure and provide better image quality (7). 99mTc-labeled compounds
demonstrate little redistribution, which allows for injections during exercise and
measures of peak exercise perfusion at a delayed imaging time (39). Additionally, the
biodistrubtion and kinetics of these compounds make it possible to perform lower
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(38). One 99mTc-labeled tracer in particular, 99mTc-sestamibi, has been incorporated in
several studies examining lower extremity perfusion in PAD. It has revealed improved
sensitivity for detecting differences in resting perfusion between the lower extremities of
patients with unilateral disease and greater sensitivity when compared with Doppler
ultrasound for detection of PAD (5). Preliminary data from our lab have shown that
SPECT/CT imaging with 99mTc-tetrofosmin also has potential for assessing regional
differences in lower extremity perfusion in PAD patients with abnormal CT angiography
and ABI findings (5). SPECT/CT has detected perfusion abnormalities in the calves of
diagnosed PAD and asymptomatic patients, with a sensitivity (91%) and specificity
(94%) for the diagnosis of PAD while correlating well with angiographic and Doppler
findings (34, 37, 40).
To date, non-invasive imaging approaches for evaluating foot perfusion in PAD
patients have been primarily limited to assessment of superficial tissue or require
physiologic stressors. PET/CT imaging may be an option to assess lower extremity
perfusion but thus far has not been applied for evaluating foot perfusion and remains
costly due to the need for more expensive instrumentation, including an onsite cyclotron
or portable generator for isotope production (41-43). SPECT/CT perfusion imaging
which could be easily combined with clinically indicated myocardial perfusion imaging
can be performed under resting conditions and provides quantitative assessment of
microvascular perfusion within 3D angiosomes of the foot containing non-healing ulcers
that are targeted for revascularization. The ability to identify volumetric abnormalities in
microvascular perfusion under resting conditions can be of significant value in the CLI
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ambulate for treadmill exercise stress testing. SPECT/CT perfusion imaging can be
performed without the need of an intravenous contrast agent, thus offering a useful noninvasive approach for evaluating lower extremity perfusion in high risk diabetic patient
who also commonly present with coexisting impaired renal function. SPECT/CT imaging
may allow for improved assessment of diabetic patients at baseline and following
treatment, such as lower extremity revascularization. Our research team at Yale
University was the first to demonstrate the feasibility of using SPECT/CT imaging to
track serial changes in resting microvascular perfusion within 3D muscle groups of the
lower extremities (44). Additionally, we have developed and clinically translated
SPECT/CT image analysis tools for quantifying regional differences in skeletal muscle
perfusion into the calf muscles of patients with unilateral PAD (5).
PET imaging can also assess lower extremity blood flow in PAD patients (41, 42,
45-47). The primary PET radiotracer implemented in patient studies has been 15O-H2O.
It can freely diffuse into tissue and has a short half-life (~2 min), making it useful for
repeated measurements of blood flow in a single visit, at rest and during exercise, or
during vasodilator stress (41-43, 45, 47-49). An 15O-H2O rest–stress PET study found
significant differences in flow reserve within the calves of PAD patients when compared
with healthy volunteers (41). Another study found significantly reduced exercise-induced
muscle blood flow in the distal legs of PAD patients who were referred for lower
extremity amputation (45). These findings suggested that 15O-H2O PET imaging may be
a valuable tool for determining subsequent amputations (45). Another group, Kalliokoski
et al., showed that PET assessment of blood flow and oxygen uptake in lower extremity
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they observed substantial variability in baseline PET flow measurements and therefore
additional assessment tools such as angiography may be required for thorough evaluation
of PAD patients. PET imaging of preclinical animal models of PAD have been used to
evaluate lower extremity rest and stress blood flow and have demonstrated a high
correlation between PET and microsphere-derived blood flow values (46, 50). In a
murine model of PAD, PET imaging with 13N-ammonia has been used to assess acute
and chronic changes in lower extremity perfusion, showing a close correlation between
PET perfusion results and histologic analysis of tissue fibrosis and necrosis (46).
Although PET imaging has proven to be useful for evaluating the lower extremities, the
short half-life of available tracers can also present a limitation for PET imaging. PET
stress imaging has traditionally required the use of exercise ergometers that are attached
to scanners, as images must be acquired during or immediately after exercise. The
development of an 18F-labeled perfusion agent (flurpiridaz) for myocardial perfusion
assessment, however, may assist with exercise PET imaging of both the heart and the
lower extremities. The longer half-life (~110 min) allows for tracer injection during peak
treadmill exercise and then serial evaluation of myocardial and skeletal muscle stress
perfusion. The high extraction fraction of 18F-flurpiridaz in the myocardium may offer
an advantage for evaluating lower extremity skeletal muscle blood flow but this
possibility still needs to be established (51).
In the present study, we further translate SPECT/CT imaging to evaluate resting
microvascular perfusion within 3D foot angiosomes in diabetic patients with CLI using a
recently developed approach for segmentation of CT attenuation images of the foot (52).

- 14 In addition to our novel approach for 3D segmentation of the foot and analysis of
angiosome perfusion, we translate previously developed image registration tools to assess
serial changes in perfusion within segmented angiosomes following revascularization
(53).

- 15 STATEMENT OF PURPOSE
Background and Motivation
Impaired lower extremity perfusion is a hallmark of peripheral arterial disease
(PAD) and is particularly problematic in the setting of diabetes mellitus (DM), which is
associated with high rates of PAD, foot ulceration, and lower extremity amputation. The
ability to non-invasively detect deficits in microvascular perfusion within threedimensional (3D) vascular territories, or angiosomes, of the feet may provide information
related to tissue viability and guide future therapeutic interventions. In this study, the
overarching goal was to evaluate the utility of single photon emission computed
tomography (SPECT)/CT imaging for quantifying volumetric microvascular perfusion
within specific angiosomes of the foot containing non-healing ulcers in DM patients with
critical limb ischemia (CLI).

Hypotheses and Aims
Hypothesis 1: SPECT/CT imaging of microvascular perfusion in foot angiosomes
provides a quantitative approach for assessing underlying pathophysiology of the foot
under resting conditions.
Aim 1: Compare resting angiosome perfusion between healthy volunteers and diabetic
patients with critical limb ischemia using SPECT/CT imaging.

Hypothesis 2: SPECT/CT imaging of angiosome microvascular perfusion does not
correlate with a standard clinical index, the ankle-brachial index (ABI), which is
commonly used to assess macrovascular disease of the lower extremities.

- 16 Aim 2: Evaluate the relationship between SPECT/CT imaging of angiosome
microvascular perfusion and the ankle-brachial index, a clinically validated tool for the
assessment of PAD.

Hypothesis 3: SPECT/CT imaging allows for sensitive detection of regional changes in
microvascular perfusion within specific ulcerated angiosomes following lower extremity
revascularization and may predict short-term and long-term clinical outcomes.
Aim 3: Evaluate the utility of SPECT/CT imaging for assessing relative changes in
angiosome microvascular perfusion following lower extremity revascularization in
diabetic patients with critical limb ischemia and relate serial changes in angiosome
perfusion to rates of limb salvage.

- 17 METHODS
Subject Recruitment
A prospective single-center study was
performed in 41 adult patients (age, 66 ± 12
years) with peripheral arterial disease and
diabetes. All patients suffered from critical limb
ischemia in the form of non-healing foot ulcers or
resting pain in the foot and/or calf. Inclusion
criteria for patients included patients 18 years or
older with previously diagnosed diabetes (type I
or II), based on any of the following criteria:
fasting plasma glucose greater than 126 mg/dl on
2 separate occasions, glycated hemoglobin
(HbA1c) greater than 6.5%, two-hour plasma

Figure 2. Patient Selection.

glucose ≥200 mg/dL in an oral glucose tolerance test; previously established history of
peripheral arterial disease via abnormal Ankle-Brachial Index (<0.9 or ³1.3), history of
lower extremity rest pain, tissue loss, or presence of non-healing ulcer. Upon enrollment,
demographic information, clinical history, and location and severity of any non-healing
ulcers were documented. Patients scheduled for lower extremity peripheral angiography
as part of their assessment and treatment were prospectively enrolled into the study. An
illustration of our subject enrollment considerations is shown in Figure 2.

- 18 Healthy control subjects (n=9) were also recruited from Yale University, YaleNew Haven Hospital, and the greater New Haven area using a research flyer. They were
screened using a standard medical history questionnaire and a physical activity
questionnaire. Subjects who did not have any exclusion criteria including preexisting
coronary artery disease, peripheral arterial disease, diabetes, cancer, hypertension,
smoking history, proceeded with standard PAD screening. PAD screening included
Ankle-Brachial Indices (ABIs) of both lower extremities. Additionally, in order to screen
for major coronary
disease, we recorded
subjects’ resting blood
pressure and heart rate.
Inclusion and exclusion
criteria are described in
Figure 3.

Figure 3. Healthy Control and CLI subject inclusion and exclusion
criteria for enrollment.

Yale University’s Human Investigation Committee and Radiation Safety Board
approved the study protocol and informed consent was obtained from all patients and
healthy volunteers.

- 19 Clinical SPECT/CT Imaging Protocol
All patients and healthy volunteers underwent baseline single photon emission
computed tomography (SPECT)/CT perfusion imaging of the lower extremities at YaleNew Haven Hospital’s Nuclear Cardiology clinical laboratory using a standard clinical
imaging protocol, following the American Society of Nuclear Cardiology guidelines. All
SPECT/CT images were acquired at the level of the ankle and foot using a conventional
hybrid SPECT/4-slice CT imaging system with large field-of-view sodium iodide (NaI)
detectors (Infinia Hawkeye, GE Healthcare) using a 360º step and shoot acquisition with
a 140.5 keV±10% window, 3º
projections, and 30 seconds per
stop. All subjects received a low
dose (14.9 ± 1.0 mCi, 551.3 ± 37
MBq) intravenous injection of
technetium-99m (99mTc)-

Figure 4. SPECT/CT Imaging Protocol.

tetrofosmin under resting conditions and underwent SPECT/CT imaging 15 minutes
following radiotracer injection (Figure 4). Immediately following the SPECT acquisition,
CT images were acquired with a slice thickness of 5 mm, at 140 kVp, and 2.5 mA for the
purposes of attenuation correction and future image segmentation of foot angiosomes.
Diabetic patients with CLI who were scheduled for lower extremity
revascularization therapy (balloon angioplasty and/or stenting) underwent additional
99m

Tc-tetrofosmin SPECT/CT perfusion imaging 1 to 3 days post-procedure, prior to

hospital discharge, to examine relative changes in microvascular perfusion in the
angiosome containing the non-healing foot ulcer.

- 20 All SPECT images were reconstructed using iterative reconstruction applying
corrections for attenuation, scatter, and resolution loss. SPECT/CT images were
reconstructed using system software (Xeleris, GE Healthcare, Buckinghamshire, UK)
capable of generating co-registered functional (SPECT) and anatomical (CT) maps of the
feet. SPECT images were reconstructed and fused with CT attenuation images.
SPECT/CT Image Analysis
SPECT/CT images were analyzed using
an image analysis toolkit (BioImage Suite,
http://www.bioimagesuite.org) developed at
Yale University and previously utilized for
regional assessment of lower extremity tissue
perfusion and oxygenation (2, 5, 44, 52, 54, 55)
Low-dose CT attenuation images were used to

Figure 5. Volume rendered foot
angiosomes overlaid on CT attenuation
images. A) Medial, B) lateral, and C)
posterior views display the medial heel
(orange), lateral heel (yellow), dorsal foot
(green), medial plantar (blue), and lateral
plantar (red) angiosomes.

segment and define five angiosomes of the feet
(lateral plantar, medial plantar, lateral calcaneal, medial calcaneal, dorsal foot; Figure 5).
Average radiotracer uptake was assessed from co-registered SPECT images within the
CT-defined three-dimensional (3D) angiosome containing the non-healing ulcer. Average
SPECT intensity values for the angiosome containing the non-healing ulcer were
normalized to injected dose of radiotracer (mCi) and patient body weight (kg) to generate
standardized uptake values (SUVs). In healthy volunteers who did not have foot
ulceration, average SPECT activity was assessed across the entire foot of their dominant
leg.

- 21 In diabetic patients who underwent SPECT/CT perfusion imaging before and after
lower extremity revascularization, serial images were co-registered using an automated
approach of rigid and non-rigid image registration previously developed and published
within the principal investigator’s laboratory thus ensuring serial perfusion analysis of the
same 3D angiosome before and after revascularization (52, 53). Changes in angiosome
perfusion were ultimately expressed as the percent change in SUV from baseline to postrevascularization.
Evaluation of Clinical Outcomes
Rates of re-intervention, wound healing, and limb salvage were evaluated in CLI
patients at 3, 6, and 12 months following lower extremity revascularization. Percent
changes in SPECT angiosome perfusion were compared between patients who underwent
an amputation versus patients who did not undergo an amputation in the first 3, 6, and 12
months following lower extremity revascularization.
99m

Tc-tetrofosmin SPECT/CT Imaging and Radiation Safety
Due to concerns regarding the amount of ionizing radiation that patients receive

with diagnostic imaging, it is prudent that all measures be taken to maintain the ALARA
(as low as reasonably achievable) principle. A low-dose (~15 mCi) injection of

99m
Tc-

tetrofosmin, which possesses a relatively short half-life of 6 hours, is associated with ~3
mSv of ionizing radiation, while CT attenuation scans of the feet immediately after the
SPECT acquisition are associated with ~0.3-0.4 mSv, thus making total exposure similar
to that of PET/CT perfusion imaging. Total radiation doses remained well within current
standard clinical limits. Of note, CT images were acquired at the level of the foot and
ankle where no vital organs were exposed to X- rays and associated radiation risk was

- 22 low.
Statistical Analysis
Unpaired t-tests were used to identify differences in baseline SPECT perfusion
values (i.e. SUVs) and baseline ABIs between healthy volunteers and diabetic patients
with CLI. Pearson’s correlation coefficient was used to assess the relation between
baseline SPECT perfusion values and baseline ABI measurements. A paired t-test was
used to identify differences between the SPECT and ABI responses to revascularization
in diabetic patients. Unpaired t-tests were used to identify differences between SPECT
perfusion changes for patient groups (amputation or no amputation) at each outcome time
point (3, 6, and 12 months after revascularization). All statistical analyses were
performed using commercially available software (GraphPad Prism v6.0 for Mac OS X,
GraphPad Software, La Jolla, CA). Statistical significance for all analyses was set at P <
0.05. All values are expressed as means ± SD unless stated otherwise.

- 23 RESULTS
A total of 41 diabetic patients
with CLI and 9 healthy control subjects
were recruited into the study. Subject
group characteristics are summarized in
Table 1. The healthy control subjects
presented with normal ABIs and did not
have a history of diabetes or other
cardiovascular co-morbidities. The CLI
patients were on average obese,
presented with abnormal ABI measures,
and had numerous cardiovascular comorbidities, such as a history of

Table 1. Demographics of diabetic patients with CLI
and healthy control subjects. *, significantly
different from control subjects (p < 0.0.5).

smoking.
Of the 41 CLI patients initially scheduled for endovascular revascularization
procedure, only 30 underwent their scheduled procedure. Only 24 of the initial 41 CLI
patients recruited
underwent post-procedure
SPECT/CT imaging.
Patient retention is
illustrated in Figure 6.

Figure 6. CLI Patient Recruitment.

- 24 Significant differences in ABI
measurements between CLI patients (0.62 ±
0.22, n = 29) and healthy control subjects (1.05
± 0.11, n = 9) confirmed the presence of PAD in
the diabetic patient population (p < 0.0001;
Figure 7). Of note, only 29 of 41 recruited CLI
patients had ABI measurements available.
SPECT/CT Imaging of Baseline Angiosome
Perfusion
99m

Figure 7. Comparison of ABI in healthy
control subjects and diabetic patients with
CLI. Healthy control subjects
demonstrated significantly higher ABI
measures compared to CLI patients.

Tc-tetrofosmin SPECT/CT imaging

of perfusion within specific angiosomes containing non-healing ulcers demonstrated a
significant difference in baseline perfusion
values (SUVs) between diabetic patients
with CLI and healthy control subjects (p =
0.02; Figure 8).
SPECT/CT perfusion imaging
revealed the appearance of decreased foot
perfusion in CLI patients who presented
with multiple signs of lower extremity
disease (Figure 9), including non-healing
foot ulcers (Figure 9A, 9B), decreased
pressure waveforms (Figure 9C), and
arterial occlusion (Figure 9D).

Figure 8. Comparison of SPECT perfusion in
healthy control subjects and diabetic patients
with CLI. Baseline SPECT SUVs in the feet of
healthy subjects were significantly higher than
SUVs in foot angiosomes containing nonhealing ulcers in CLI patients.
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Figure 9. A) Dorsal and B) plantar views of a non-healing ulcer in a patient with
C) decreased pressure waveforms and D) superficial femoral artery occlusion, as
identified by angiography (occlusion denoted by yellow arrow). E) Sagittal, F)
axial, and G) coronal SPECT/CT images reveal decreased resting perfusion in
the distal foot (2).

Correlation of SPECT/CT Perfusion Imaging with Standard Assessment Tools
Analysis of baseline SPECT/CT
imaging and ABI measurements in CLI
patients and healthy control subjects
demonstrated a significant and positive
relationship between SPECT/CT angiosome
perfusion and ABI (p = 0.01; r = 0.41;
Figure 10).
Evaluation of Serial Changes in Angiosome
Perfusion Using SPECT/CT Imaging
SPECT/CT imaging of CLI patients
undergoing lower extremity endovascular

Figure 10. Relationship between ABI and
baseline SPECT perfusion. ABI was
significantly and positively related to baseline
SPECT SUVs when collectively assessing
healthy controls and CLI patients; however,
more scatter among CLI patient data points
suggests a weaker relationship in the setting of
DM. n=9 healthy controls, n=29 CLI patients.

revascularization demonstrated the ability to detect resting deficits in angiosome foot

- 26 perfusion before intervention
within areas of ulceration
(Figure 11A, 11B), as well as
allowed for visualization of
improvements in angiosome
perfusion following
revascularization (Figure 11C).
Serial evaluation of
relative changes in SPECT
angiosome foot perfusion

Figure 11. SPECT/CT perfusion imaging in diabetic patient
with CLI before and after lower extremity revascularization
treatment. A) Patient displaying diabetic non-healing ulcer on
plantar aspect of right great toe. B) Axial SPECT/CT
perfusion images demonstrate perfusion defect in region of
right great toe before revascularization (ischemic area
denoted by white arrows). C) SPECT/CT perfusion imaging
after revascularization demonstrates increased perfusion to
the right great toe (denoted by yellow arrows).

following revascularization revealed significant quantitative changes in perfusion after
treatment (Figure 12) whereas ABI measurements did not demonstrate significant
changes after revascularization (Figure 13).

Figure 12. Evaluation of serial changes
in SPECT SUVs in CLI patients
undergoing revascularization. SPECT
SUVs showed a significant increase
following lower extremity
revascularization.

Figure 13. Evaluation of serial changes
in ABI in CLI patients undergoing
revascularization. ABI measures did not
significantly increase following lower
extremity revascularization.

- 27 Of note, only 24 of 41 recruited CLI patients had post-procedure SPECT/CT imaging and
only 9 of 41 recruited CLI patients had ABI measurements taken before and after
revascularization procedure.
Clinical Outcomes
Long-term follow-up of CLI patients at 12 months demonstrated 68 percent of
patients had an at least one major (above the ankle) or minor (below the ankle) ampuation
(Figure 14A). 19.5 percent of patients were deceased at 12 months (Figure 14B). 19.5
percent of patients had evidence that their initial wounds had healed (Figure 14C). Note,
this is not to say they did not develop subsequent wounds. 48.7 percent of patients had

Figure 14. CLI patients’ clinical outcomes 12 months after baseline SPECT/CT
imaging. (A) 12 months after baseline imaging, 68 percent of CLI patients had
undergone a major (above the ankle) or minor (below the ankle) amputation, (B) 19.5
percent were deceased, (C) 19.5 percent experienced wound healing, and (D) 48.7
percent of patients required at least one re-intervention procedure. n=41 CLI patients.

- 28 undergone at least one revasculariztion intervention due to restenosis, new symptoms
such as ischemic rest pain, or new non-healing wounds (Figure 14D).
Of the 24 CLI patients who had post-procedure SPECT/CT imaging, 11 had an
amputation within 3 months after revascularization (Figure 15A). There was a significant
difference between the percent changes in angiosome perfusion following
revascularization in patients with (4.99 ± 3.44%) and patients without (14.2 ± 11.3%)
amputation in the first 3 months post-procedure (Figure 15A; p = 0.01).
In the 6 months after procedure, 13 of the 24 CLI patients who underwent
revascularization had undergone an amputation. Again, the percent changes in SPECT
angiosome perfusion were significantly higher in the patients who had not undergone an
amputation (14.4 ± 12.3%) in the first 6 months post-revascularization compared to
patients who did have an amputation (6.24 ± 4.53%) (Figure 15B; p = 0.03).
In the 12 months after revascularization, 14 of the 24 CLI patients who underwent
revascularization had undergone an amputation. Again, the percent changes in SPECT
perfusion were significantly higher in patients who had not undergone an amputation

Figure 15. Changes in SPECT-derived angiosome foot perfusion in relation to limb salvage outcomes. The percent
change in SPECT SUVs after revascularization were significantly different between CLI patients who experienced limb
salvage compared to patients who underwent a minor or major lower extremity amputation in the (A) 3, (B) 6, and (C)
12 months after revascularization procedure.

- 29 (14.8 ± 12.8%) in the first 12 months after revascularization versus patients who
underwent amputation (6.50 ± 4.46%) (Figure 15C; p = 0.03).
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In the present study, we demonstrate for the first time the utility of SPECT/CT
perfusion imaging for non-invasive assessment of angiosome microvascular perfusion
under resting conditions, as well as following lower extremity endovascular
revascularization. We demonstrate that SPECT/CT imaging is sensitive for detecting
perfusion abnormalities in diabetic patients with CLI and that baseline SPECT/CT
perfusion imaging correlates loosely with a standard clinical index, the ABI.
Additionally, we demonstrate that SPECT/CT imaging allows for serial assessment of
relative changes in microvascular perfusion within angiosomes of the foot containing
non-healing ulcers following lower extremity revascularization, and that angiosome
specific changes in SPECT perfusion may relate to clinical outcomes such as rates of
limb salvage.
In the assessment of baseline angiosome foot perfusion, SPECT/CT perfusion
imaging demonstrated significantly higher perfusion values in the feet of healthy control
subjects when compared to ulcerated foot angiosomes of diabetic patients with CLI
(Figure 8), thus indicating sensitivity of SPECT/CT imaging for detecting PAD
pathology. The presence of PAD was confirmed in diabetic patients with CLI by using a
standard clinical index, the ABI, which revealed significant differences between healthy
and CLI patients (Figure 7). Prior studies have utilized SPECT/CT imaging for
assessment of PAD patients; however, this study presents a novel image segmentation
tool that allows for unique SPECT/CT imaging of regional angiosome foot perfusion
under resting conditions in a CLI patient population at high risk for lower extremity
amputation (7, 56, 57). Correlational analysis demonstrated a significant and positive
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assessment of CLI patients and healthy control subjects; however, the relationship
between SPECT perfusion and ABI was clearly more scattered when looking specifically
at CLI patient data points (Figure 10). This finding is consistent with previous studies
that have demonstrated ABI is limited in utility when assessing the diabetic patient
population, which is likely due to the high prevalence of microvascular disease and
calcification (58). Additionally, the looser relationship between SPECT and ABI within
CLI patients may be suggestive of a mismatch between microvascular perfusion (as
assessed by SPECT) and large vessel obstruction (as assessed by ABI) in the diabetic
patient population.
In addition to evaluating the utility of SPECT/CT imaging for baseline assessment
of angiosome foot perfusion, we have demonstrated the value and sensitivity of
SPECT/CT imaging for assessing the effect of lower extremity revascularization in
diabetic patients with CLI. To facilitate serial assessment of changes in angiosome
perfusion following treatment, we have translated previously developed tools for serial
image registration, which allow for reproducible assessment of perfusion within the same
3D segmented angiosomes (52, 53). Following lower extremity revascularization, our
SPECT/CT imaging approach demonstrated significant changes in angiosome perfusion
(Figure 12) that were not observed when utilizing the ABI (Figure 13), a standard clinical
tool utilized for assessing PAD patients. This data suggests that SPECT/CT perfusion
imaging is sensitive for non-invasively detecting changes in microvascular perfusion
following medical treatment, and that SPECT/CT imaging may offer benefits over the
standard ABI, which primarily assesses macrovascular pressures/patency and can be
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Additionally, the ability of SPECT/CT imaging to evaluate microvascular perfusion
might be of particular relevance in the diabetic patient population since diabetic patients
commonly suffer from concomitant macrovascular and microvascular, with the latter
being a key contributor to the formation and impaired healing process of diabetic foot
ulcers (58).
Long-term follow-up of CLI patient outcomes at 12 months post-revascularization
demonstrated similar clinical outcomes to those previously reported in clinical trials aside
from our amputation rates, which were slightly higher (8). This may be a reflection of
wound severity in our CLI patient populating, in particular, infection and the fact these
patients were already scheduled for intervention perhaps indicating wound severity.
Specifically, 68 percent of patients had an at least one major (above the ankle) or minor
(below the ankle) ampuation (Figure 14A), while 19.5 percent of patients were deceased
by 12 months (Figure 14B) and only 19.5 percent experienced wound healing (Figure
14C). Additionally, 48.7 percent of patients required at least one additional
revasculariztion procedure due to restenosis, new symptoms such as ischemic rest pain,
or new non-healing wounds (Figure 14D). This data is in agreement with prior clinical
studies that have demonstrated similar rates of re-intervention in the CLI patient
population (8, 59).
Prior research studies have applied non-invasive imaging for the evaluation of
responses to medical treatment in PAD patients, however, to date, there has been a lack
of clinical studies that have related findings from non-invasive imaging to clinical
outcomes (60, 61). In the present study, we found that our SPECT/CT imaging approach
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Specifically, we found that patients who experienced poor improvements in angiosome
perfusion following revascularization (i.e. 5 to 6 percent) ultimately experienced a minor
or major amputation of the lower extremity, whereas patients experiencing greater
improvements in angiosome perfusion (i.e. 14 to 15 percent) experienced limb salvage up
to 3, 6, and 12 months after revascularization procedure (Figure 15). These findings
suggest that SPECT/CT perfusion may possess significant value for the assessment of
treatment responses in PAD patients and could assist clinical decisions in the time period
immediately following medical treatment.
To date, non-invasive imaging approaches for evaluating foot perfusion in PAD
patients have been primarily limited to assessment of superficial tissue or require
physiologic stressors (22). CT and MR angiography can both offer valuable anatomical
information, however, CT angiography requires exposure to radiation and iodinated
contrast material and its utility is reduced in the setting of calcified vessels, particularly in
the smaller vessels of the calf and foot (19). In comparison to CT angiography, MR
angiography does not require radiation or iodinated contrast, but MR angiography does
use gadolinium contrast agents, which cannot be used in cases of severe renal failure.
Additionally, MR is hindered in the presence of non-compatible pacemakers or metal
implants (including stents) (19, 22). DSA remains the gold standard for imaging tools in
assessing PAD since it allows for high spatial resolution imaging of vascular occlusions,
but it is an invasive procedure and carries the risk of complications, including hematoma,
pseudoaneurysm, dissection and arteriovenous fistula (6). Additionally, it requires intraarterial delivery of iodinated contrast, and is limited in its inability to characterize vessel
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perfusion but thus far has not been applied for evaluating foot perfusion and remains
costly due to the need for more expensive instrumentation (41-43). SPECT/CT perfusion
imaging could be easily combined with clinically indicated myocardial perfusion
imaging, can be performed under resting conditions, and provides quantitative assessment
of microvascular perfusion within 3D angiosomes of the foot containing non-healing
ulcers that are targeted for revascularization. Many CLI patients are unable to ambulate
for treadmill exercise stress testing and many of these high-risk patients also commonly
present with impaired renal function. Therefore, the ability to derive potentially valuable
clinical information in CLI patients under resting conditions without the need for an
intravenous contrast agent may lead to lower extremity SPECT/CT perfusion imaging
becoming a clinically valuable tool in the near future.
One limitation of this study is the imaging approach has not been fully validated.
We could validate this approach by evaluating test-retest reliability. In the future we
could also expand our imaging approach to assess patients along the entire spectrum of
PAD and not just the most severe cases, such as CLI. Additionally, we may investigate
the utility of stress SPECT/CT perfusion imaging of the lower extremity which could be
combined with clinically indicated cardiac perfusion imaging.
In the present study, we apply SPECT/CT imaging to evaluate resting
microvascular perfusion within 3D foot angiosomes in diabetic patients with CLI using a
recently developed approach for segmentation of CT attenuation images of the foot (52).
In addition to our novel approach for 3D segmentation of the foot and analysis of
angiosome perfusion, we translate previously developed image registration tools to assess
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(53). Lastly, we show SPECT/CT imaging of angiosome perfusion may be able to predict
short- and long-term limb salvage outcomes for CLI patients undergoing lower extremity
revascularization procedures. Therefore, our results demonstrate that, 99mTc-tetrofosmin
SPECT/CT perfusion imaging may be useful for the evaluation of various types of
targeted therapies in PAD, such as revascularization procedures, exercise therapy, and
novel gene therapies. Additionally, SPECT/CT imaging may be useful in assessing early
response to treatment, thereby providing clinicians with an early indication of treatment
efficacy and potentially guiding further treatment. Future application of SPECT/CT
imaging may provide additional value for detection of ischemic regions of the foot, as
well as assist with risk stratification. Further evaluation of the sensitivity of SPECT/CT
imaging in predicting wound healing and limb salvage in a large clinical trial of PAD
patients undergoing medical treatment is warranted and could elucidate the true clinical
utility of this imaging approach.
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